Centogene N.V. Net Income 2011-2025 | CNTG

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Centogene N.V.

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-46.9 M	-21.4 M	-20.9 M	-11.3 M	-5.48 M	-5.36 M	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
-5.36 M	-46.9 M	-18.5 M

Quarterly Net Income Centogene N.V.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-6.48 M	-	-21.6 M	-8.02 M	-4.89 M	-	-5.64 M	-10.4 M	-8.74 M	-	-4.28 M	-6.28 M	-5.28 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-4.28 M	-21.6 M	-8.16 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Diagnostics research industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Akumin AKU	-157 M	-	-17.87 %	$ 25.9 M	Canada
Chembio Diagnostics CEMI	-23.3 M	-	0.22 %	$ 16.8 M	USA
Brainsway Ltd. BWAY	-6.46 M	$ 19.29	-1.73 %	$ 99.4 M	Israel
Castle Biosciences CSTL	18.2 M	$ 40.09	-0.27 %	$ 1.11 B	USA
Burning Rock Biotech Limited BNR	-797 M	$ 21.26	-2.34 %	$ 229 M	China
Accelerate Diagnostics AXDX	-14.6 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-32.1 M	-	-13.05 %	$ 7.29 M	USA
Danaher Corporation DHR	3.9 B	$ 231.47	0.28 %	$ 169 B	USA
DarioHealth Corp. DRIO	-59.4 M	$ 10.04	-0.99 %	$ 285 M	Israel
DexCom DXCM	542 M	$ 67.42	0.84 %	$ 26 B	USA
Enzo Biochem ENZ	-26.1 M	-	-8.98 %	$ 14.8 K	USA
BioNano Genomics BNGO	-112 M	$ 1.52	-0.65 %	$ 1.93 M	USA
Exact Sciences Corporation EXAS	-865 M	$ 101.54	-0.05 %	$ 18.8 B	USA
Oxford Immunotec Global PLC OXFD	-1.81 M	-	-	$ 562 M	Britain
HTG Molecular Diagnostics HTGM	-21.6 M	-	-20.0 %	$ 1.06 M	USA
Fulgent Genetics FLGT	-42.7 M	$ 27.01	-0.55 %	$ 817 M	USA
Global Cord Blood Corporation CO	501 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-53 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-7.13 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-503 M	-	0.12 %	$ 80.1 M	China
DermTech DMTK	-101 M	-	-11.32 %	$ 2.94 M	USA
PRA Health Sciences, Inc. PRAH	197 M	-	-	$ 10.7 B	USA
CareDx, Inc CDNA	-190 M	$ 19.73	-1.45 %	$ 1.06 B	USA
Celcuity CELC	-112 M	$ 102.61	0.25 %	$ 4.05 B	USA
Anixa Biosciences ANIX	-12.6 M	$ 3.42	3.64 %	$ 109 K	USA
Co-Diagnostics CODX	-35.3 M	$ 0.24	-1.79 %	$ 7.04 M	USA
IQVIA Holdings IQV	1.37 B	$ 226.02	0.39 %	$ 41 B	USA
Motus GI Holdings MOTS	-12.9 M	-	-34.28 %	$ 263 K	Israel
Guardant Health GH	-436 M	$ 102.38	-0.12 %	$ 12.6 B	USA
NeoGenomics NEO	-78.7 M	$ 12.3	-0.97 %	$ 1.56 B	USA
Neogen Corporation NEOG	-1.09 B	$ 7.14	-0.14 %	$ 1.55 B	USA
Aspira Women's Health AWH	-27.2 M	-	-6.19 %	$ 10.5 M	USA
National Research Corporation NRC	31 M	$ 18.81	-1.05 %	$ 462 M	USA
Heska Corporation HSKA	-19.9 M	-	-	$ 1.31 B	USA
Organovo Holdings ONVO	-2.49 M	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	12 M	-	-16.95 %	$ 1.54 M	USA
OPKO Health OPK	14 M	$ 1.3	-0.76 %	$ 902 M	USA
Mettler-Toledo International MTD	863 M	$ 1 417.16	0.18 %	$ 30.1 B	Schweiz
Illumina ILMN	-1.22 B	$ 135.32	-0.64 %	$ 21.5 B	USA
Charles River Laboratories International CRL	22.2 M	$ 203.16	0.14 %	$ 10.4 B	USA
ENDRA Life Sciences NDRA	-11.5 M	$ 5.1	-	$ 2.74 M	USA
Pacific Biosciences of California PACB	-307 M	$ 1.88	3.3 %	$ 477 M	USA
PerkinElmer PKI	270 M	-	-0.91 %	$ 14.7 B	USA
Quest Diagnostics Incorporated DGX	871 M	$ 175.92	0.48 %	$ 19.5 B	USA
Biodesix BDSX	-42.9 M	$ 6.82	1.04 %	$ 884 M	USA
Myriad Genetics MYGN	-127 M	$ 6.55	-0.15 %	$ 593 M	USA
Laboratory Corporation of America Holdings LH	746 M	$ 254.46	0.52 %	$ 21.3 B	USA
ICON Public Limited Company ICLR	791 M	$ 183.68	0.33 %	$ 15.2 B	Irlanda
IDEXX Laboratories IDXX	888 M	$ 688.18	0.86 %	$ 56.8 B	USA